首页> 外文期刊>Applied biochemistry and biotechnology, Part A. enzyme engineering and biotechnology >Statins: 3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors demonstrate anti-atherosclerotic character due to their antioxidant capacity
【24h】

Statins: 3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors demonstrate anti-atherosclerotic character due to their antioxidant capacity

机译:他汀类药物:3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂由于具有抗氧化能力,因此具有抗动脉粥样硬化的特性

获取原文
获取原文并翻译 | 示例
           

摘要

Atherosclerosis is a chronic inflammatory disease of multiple etiologies. It is associated with the accumulation of oxidized lipids in arterial lesions leading to coronary heart disease. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (commonly known as statins) are widely used in cardiovascular disease prevention to lower the cholesterol. The antioxidant activity of HMG-CoA reductase inhibitors was studied by lipid peroxidation inhibition assay, DPPH, and hydroxyl radical scavenging-activity methods. The lovastatin (93%) and simvastatin (96%) showed significant action of lipid peroxidation inhibition compared to other HMG-CoA reductase inhibitors. The DPPH radical and hydroxyl radical scavenging activity of simvastatin was 38% and 33%, respectively. The oxidative modification of serum lipid due to reactive oxygen species causes atherosclerosis. This study revealed the importance of lovastatin and simvastatin to prevent oxidative stress-related cardiovascular diseases.
机译:动脉粥样硬化是多种病因的慢性炎性疾病。它与导致冠心病的动脉病变中氧化脂质的积累有关。 3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂(俗称他汀类)广泛用于预防心血管疾病,以降低胆固醇。 HMG-CoA还原酶抑制剂的抗氧化活性通过脂质过氧化抑制试验,DPPH和清除羟基自由基的方法进行了研究。与其他HMG-CoA还原酶抑制剂相比,洛伐他汀(93%)和辛伐他汀(96%)表现出明显的脂质过氧化抑制作用。辛伐他汀的DPPH自由基和羟基自由基清除活性分别为38%和33%。由于活性氧引起的血清脂质的氧化修饰导致动脉粥样硬化。这项研究揭示了洛伐他汀和辛伐他汀对预防氧化应激相关心血管疾病的重要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号